Cryoport affirms $192M-$196M 2026 revenue guidance while targeting continued adjusted EBITDA expansion (NASDAQ:CYRX)
· seekingalpha.com
Cryoport (CYRX) Q2 2026 earnings call recap: $49M revenue, positive EBITDA, 2026 guidance affirmed, and cell & gene therapy outlook—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...